Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B

Hye Soo Kim; Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Do Young Kim; Ki Jun Song; Jung Won Park; Yeong Jin Kim; Oidov Baatarkhuu; Kwang Hyub Han; Sang Hoon Ahn

doi:10.1016/j.cgh.2016.05.039

Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B

Hye Soo Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Ki Jun Song, Jung Won Park, Yeong Jin Kim, Oidov Baatarkhuu, Kwang Hyub Han, Sang Hoon Ahn

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

Background & Aims We performed a propensity-score matched analysis to investigate whether entecavir, compared with lamivudine, can reduce risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B after adjusting for level of fibrosis. Methods We performed a retrospective study of 1079 patients with chronic hepatitis B who received first-line therapy with lamivudine (n = 435) or entecavir (n = 644) from 2006 through 2013. Only patients with available liver stiffness value measured by transient elastography were recruited. Liver cirrhosis was diagnosed by ultrasonography. To adjust for the imbalance of patients treated with lamivudine versus entecavir, we performed propensity-score matching (PSM), at a ratio of 1:1, using 7 factors (age, sex, hepatitis B e antigen, alanine aminotransferase, serum albumin, platelet count, and liver stiffness; PSM1) or 8 factors (variables of PSM1 plus ultrasonography measurements of cirrhosis; PSM2). Patients with virologic breakthrough or resistance mutations received rescue therapy. Results Over the 7-year period, 91 patients developed HCC and 104 had liver-related events in the entire cohort. In multivariate analyses, level of fibrosis, but not antiviral regimen, was independently associated with risk of HCC (P <.05). The PSM1 group included 342 pairs of patients and the PSM2 group included 338 pairs. Similar proportions of patients given lamivudine versus entecavir developed HCC in each model (10.5% given lamivudine vs 9.9% given entecavir in PSM1 and 11.9% vs 12.6% in PSM2; all P >.05). When PSM was applied to patients with liver stiffness value ≤13 kPa or >13 kPa, patients given lamivudine versus entecavir still had similar cumulative rates of HCC development (all P >.05). Conclusions In a PSM analysis, we associated level of fibrosis, rather than antiviral regimen, with risk of HCC, when patients received appropriate rescue therapy in case of virologic breakthrough or resistance mutations.

Original language	English
Pages (from-to)	1647-1656.e6
Journal	Clinical Gastroenterology and Hepatology
Volume	14
Issue number	11
DOIs	https://doi.org/10.1016/j.cgh.2016.05.039
Publication status	Published - 2016 Nov 1

Bibliographical note

Funding Information:
Funding This study was supported by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning ( 2016R1A1A1A05005138 ) and by Research of Korea Centers for Disease Control and Prevention ( HD15A0351 ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Publisher Copyright:
© 2016 AGA Institute

All Science Journal Classification (ASJC) codes

Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cgh.2016.05.039

Cite this

Kim, H. S., Kim, B. K., Kim, S. U., Park, J. Y., Kim, D. Y., Song, K. J., Park, J. W., Kim, Y. J., Baatarkhuu, O., Han, K. H., & Ahn, S. H. (2016). Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 14(11), 1647-1656.e6. https://doi.org/10.1016/j.cgh.2016.05.039

Kim, Hye Soo ; Kim, Beom Kyung ; Kim, Seung Up ; Park, Jun Yong ; Kim, Do Young ; Song, Ki Jun ; Park, Jung Won ; Kim, Yeong Jin ; Baatarkhuu, Oidov ; Han, Kwang Hyub ; Ahn, Sang Hoon. / Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. In: Clinical Gastroenterology and Hepatology. 2016 ; Vol. 14, No. 11. pp. 1647-1656.e6.

@article{b87f4232ea8f4e9aa23539d39557a7ab,

title = "Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B",

abstract = "Background & Aims We performed a propensity-score matched analysis to investigate whether entecavir, compared with lamivudine, can reduce risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B after adjusting for level of fibrosis. Methods We performed a retrospective study of 1079 patients with chronic hepatitis B who received first-line therapy with lamivudine (n = 435) or entecavir (n = 644) from 2006 through 2013. Only patients with available liver stiffness value measured by transient elastography were recruited. Liver cirrhosis was diagnosed by ultrasonography. To adjust for the imbalance of patients treated with lamivudine versus entecavir, we performed propensity-score matching (PSM), at a ratio of 1:1, using 7 factors (age, sex, hepatitis B e antigen, alanine aminotransferase, serum albumin, platelet count, and liver stiffness; PSM1) or 8 factors (variables of PSM1 plus ultrasonography measurements of cirrhosis; PSM2). Patients with virologic breakthrough or resistance mutations received rescue therapy. Results Over the 7-year period, 91 patients developed HCC and 104 had liver-related events in the entire cohort. In multivariate analyses, level of fibrosis, but not antiviral regimen, was independently associated with risk of HCC (P <.05). The PSM1 group included 342 pairs of patients and the PSM2 group included 338 pairs. Similar proportions of patients given lamivudine versus entecavir developed HCC in each model (10.5% given lamivudine vs 9.9% given entecavir in PSM1 and 11.9% vs 12.6% in PSM2; all P >.05). When PSM was applied to patients with liver stiffness value ≤13 kPa or >13 kPa, patients given lamivudine versus entecavir still had similar cumulative rates of HCC development (all P >.05). Conclusions In a PSM analysis, we associated level of fibrosis, rather than antiviral regimen, with risk of HCC, when patients received appropriate rescue therapy in case of virologic breakthrough or resistance mutations.",

author = "Kim, {Hye Soo} and Kim, {Beom Kyung} and Kim, {Seung Up} and Park, {Jun Yong} and Kim, {Do Young} and Song, {Ki Jun} and Park, {Jung Won} and Kim, {Yeong Jin} and Oidov Baatarkhuu and Han, {Kwang Hyub} and Ahn, {Sang Hoon}",

note = "Funding Information: Funding This study was supported by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning ( 2016R1A1A1A05005138 ) and by Research of Korea Centers for Disease Control and Prevention ( HD15A0351 ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: {\textcopyright} 2016 AGA Institute",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/j.cgh.2016.05.039",

language = "English",

volume = "14",

pages = "1647--1656.e6",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "11",

}

Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. / Kim, Hye Soo; Kim, Beom Kyung; Kim, Seung Up ; Park, Jun Yong ; Kim, Do Young; Song, Ki Jun; Park, Jung Won; Kim, Yeong Jin; Baatarkhuu, Oidov; Han, Kwang Hyub ; Ahn, Sang Hoon.

In: Clinical Gastroenterology and Hepatology, Vol. 14, No. 11, 01.11.2016, p. 1647-1656.e6.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B

AU - Kim, Hye Soo

AU - Kim, Beom Kyung

AU - Kim, Seung Up

AU - Park, Jun Yong

AU - Kim, Do Young

AU - Song, Ki Jun

AU - Park, Jung Won

AU - Kim, Yeong Jin

AU - Baatarkhuu, Oidov

AU - Han, Kwang Hyub

AU - Ahn, Sang Hoon

N1 - Funding Information: Funding This study was supported by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning ( 2016R1A1A1A05005138 ) and by Research of Korea Centers for Disease Control and Prevention ( HD15A0351 ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: © 2016 AGA Institute

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background & Aims We performed a propensity-score matched analysis to investigate whether entecavir, compared with lamivudine, can reduce risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B after adjusting for level of fibrosis. Methods We performed a retrospective study of 1079 patients with chronic hepatitis B who received first-line therapy with lamivudine (n = 435) or entecavir (n = 644) from 2006 through 2013. Only patients with available liver stiffness value measured by transient elastography were recruited. Liver cirrhosis was diagnosed by ultrasonography. To adjust for the imbalance of patients treated with lamivudine versus entecavir, we performed propensity-score matching (PSM), at a ratio of 1:1, using 7 factors (age, sex, hepatitis B e antigen, alanine aminotransferase, serum albumin, platelet count, and liver stiffness; PSM1) or 8 factors (variables of PSM1 plus ultrasonography measurements of cirrhosis; PSM2). Patients with virologic breakthrough or resistance mutations received rescue therapy. Results Over the 7-year period, 91 patients developed HCC and 104 had liver-related events in the entire cohort. In multivariate analyses, level of fibrosis, but not antiviral regimen, was independently associated with risk of HCC (P <.05). The PSM1 group included 342 pairs of patients and the PSM2 group included 338 pairs. Similar proportions of patients given lamivudine versus entecavir developed HCC in each model (10.5% given lamivudine vs 9.9% given entecavir in PSM1 and 11.9% vs 12.6% in PSM2; all P >.05). When PSM was applied to patients with liver stiffness value ≤13 kPa or >13 kPa, patients given lamivudine versus entecavir still had similar cumulative rates of HCC development (all P >.05). Conclusions In a PSM analysis, we associated level of fibrosis, rather than antiviral regimen, with risk of HCC, when patients received appropriate rescue therapy in case of virologic breakthrough or resistance mutations.

AB - Background & Aims We performed a propensity-score matched analysis to investigate whether entecavir, compared with lamivudine, can reduce risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B after adjusting for level of fibrosis. Methods We performed a retrospective study of 1079 patients with chronic hepatitis B who received first-line therapy with lamivudine (n = 435) or entecavir (n = 644) from 2006 through 2013. Only patients with available liver stiffness value measured by transient elastography were recruited. Liver cirrhosis was diagnosed by ultrasonography. To adjust for the imbalance of patients treated with lamivudine versus entecavir, we performed propensity-score matching (PSM), at a ratio of 1:1, using 7 factors (age, sex, hepatitis B e antigen, alanine aminotransferase, serum albumin, platelet count, and liver stiffness; PSM1) or 8 factors (variables of PSM1 plus ultrasonography measurements of cirrhosis; PSM2). Patients with virologic breakthrough or resistance mutations received rescue therapy. Results Over the 7-year period, 91 patients developed HCC and 104 had liver-related events in the entire cohort. In multivariate analyses, level of fibrosis, but not antiviral regimen, was independently associated with risk of HCC (P <.05). The PSM1 group included 342 pairs of patients and the PSM2 group included 338 pairs. Similar proportions of patients given lamivudine versus entecavir developed HCC in each model (10.5% given lamivudine vs 9.9% given entecavir in PSM1 and 11.9% vs 12.6% in PSM2; all P >.05). When PSM was applied to patients with liver stiffness value ≤13 kPa or >13 kPa, patients given lamivudine versus entecavir still had similar cumulative rates of HCC development (all P >.05). Conclusions In a PSM analysis, we associated level of fibrosis, rather than antiviral regimen, with risk of HCC, when patients received appropriate rescue therapy in case of virologic breakthrough or resistance mutations.

UR - http://www.scopus.com/inward/record.url?scp=84994520006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994520006&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2016.05.039

DO - 10.1016/j.cgh.2016.05.039

M3 - Article

C2 - 27305847

AN - SCOPUS:84994520006

VL - 14

SP - 1647-1656.e6

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 11

ER -

Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this